The global drug eluting balloon catheter market is expected to be

Drug Eluting Balloon Catheters Market

Healthcare infrastructure has undergone major changes over the past decade as the proliferation of technologies has increased and healthcare research has also experienced a substantial boom. Rising obesity, increasing geriatric population and increasing prevalence of coronary heart disease are some of the factors driving the demand for drug eluting balloon catheters. When stents are used with a balloon catheter, it is called a balloon expandable stent, which differs from self-expanding stents, and these are normally made from a nitinol alloy.

The adoption of angioplasty balloons for patients who do not benefit from percutaneous coronary intervention (PCI) is also driving the growth of the drug-eluting balloon catheter (DEB) market. There is increasing support from governments and other institutions supporting research and granting funds to further develop drug-eluting balloon catheters.

???https://www.factmr.com/connectus/sample?flag=S&rep_id=146

๐—ช๐—ต๐—ฎ๐˜ ๐—ถ๐˜€ ๐˜๐—ต๐—ฒ ๐—ข๐˜‚๐˜๐—น๐—ผ๐—ผ๐—ธ ๐—ณ๐—ผ๐—ฟ ๐˜๐—ต๐—ฒ ๐—ฃ๐—ฒ๐—ฟ๐—ถ๐—ฝ๐—ต๐—ฒ๐—ฟ๐—ฎ๐—น ๐——๐—ถ๐˜€๐—ฒ๐—ฎ๐˜€๐—ฒ ๐——๐—˜๐—• ๐—–๐—ฎ๐˜๐—ต๐—ฒ๐˜๐—ฒ๐—ฟ ๐— ๐—ฎ๐—ฟ๐—ธ๐—ฒ๐˜?

The use of drug-eluting devices is primarily associated with heart conditions, and these are used to reduce the rate of restenosis. Peripheral Drug Coated Balloon Catheter market is poised to grow at a steady CAGR over the next ten years. The use of drug-eluting balloon catheters for peripheral arterial procedures is expected to increase as their benefits materialize and the procedures become more affordable.
In the indications segment, the demand for drug-eluting balloon catheters for coronary heart disease is expected to account for nearly 80% market share by value. Despite minimal market share, the demand for drug-eluting balloon catheters for peripheral vascular disease is expected to grow at a steady CAGR during the forecast period.
As more and more angioplasty balloons are researched and developed, it is estimated that the sales of drug-coated peripheral balloon catheters will also experience an upward trend.

๐—–๐—ข๐—ฉ๐—œ๐——-๐Ÿญ๐Ÿต ๐—œ๐—บ๐—ฝ๐—ฎ๐—ฐ๐˜ ๐—ผ๐—ป ๐— ๐—ฎ๐—ฟ๐—ธ๐—ฒ๐˜

The COVID-19 pandemic has massively affected healthcare infrastructure and the way it has been managed. The treatment of each disease became secondary as the focus was solely on the fight against the coronavirus. The COVID-19 pandemic has affected research and development related to drug-eluting balloon catheters and caused major disruptions in demand and supply chains.
However, in the post-pandemic era, the demand for drug-eluting balloon catheters is expected to grow rapidly. Even though the pandemic caused a major drop in sales, the market is expected to recoup the losses over the next few years as research gathers momentum.

๐—ช๐—ต๐—ฎ๐˜ ๐—ถ๐˜€ ๐˜๐—ต๐—ฒ ๐—ฅ๐—ฒ๐—ด๐—ถ๐—ผ๐—ป๐—ฎ๐—น ๐—ข๐˜‚๐˜๐—น๐—ผ๐—ผ๐—ธ ๐—ผ๐—ณ ๐˜๐—ต๐—ฒ ๐—˜๐—น๐˜‚๐˜๐—ถ๐—ป๐—ด ๐—•๐—ฎ๐—น๐—น๐—ผ๐—ผ๐—ป ๐—–๐—ฎ๐˜๐—ต๐—ฒ๐˜๐—ฒ๐—ฟ ๐— ๐—ฎ๐—ฟ๐—ธ๐—ฒ๐˜?

This research details the global Drug Eluting Balloon Catheter industry landscape across North America, Latin America, Europe, APAC and MEA regions.
Europe dominates the market and is expected to continue its dominance throughout the forecast period. The UK is expected to dominate the European market, with an excellent CAGR of around 20%.
North America is expected to be the second largest market. The market in Asia is expected to grow at the fastest CAGR during the forecast period. India and China are expected to lead the demand in the APAC region.
Adoption of drug-eluting balloon catheters in MEA is expected to accelerate as healthcare infrastructure grows in the region.

๐—š๐—ฒ๐˜ ๐—–๐˜‚๐˜€๐˜๐—ผ๐—บ๐—ถ๐˜‡๐—ฎ๐˜๐—ถ๐—ผ๐—ป ๐—ผ๐—ป ๐˜๐—ต๐—ถ๐˜€ ๐—ฅ๐—ฒ๐—ฝ๐—ผ๐—ฟ๐˜ ๐—ณ๐—ผ๐—ฟ ๐—ฆ๐—ฝ๐—ฒ๐—ฐ๐—ถ๐—ณ๐—ถ๐—ฐ ๐—ฅ๐—ฒ๐˜€๐—ฒ๐—ฎ๐—ฟ๐—ฐ๐—ต ๐—ฆ๐—ผ๐—น๐˜‚๐˜๐—ถ๐—ผ๐—ป๐˜€:https://www.factmr.com/connectus/sample?flag=RC&rep_id=146

๐—–๐—ผ๐—บ๐—ฝ๐—ฒ๐˜๐—ถ๐˜๐—ถ๐˜ƒ๐—ฒ ๐—Ÿ๐—ฎ๐—ป๐—ฑ๐˜€๐—ฐ๐—ฎ๐—ฝ๐—ฒ

Research in the field of drug-eluting balloon catheters by key players is expected to bolster the development and sales of more accurate and effective drug-eluting balloon catheters.
โ€ข In February 2021, L2Mtech GmbH obtained its first CE marking on six products. This marks a milestone in the companyโ€™s history and proves the efficacy and safety of its innovative cardiovascular and endovascular applications. The company plans to commercially launch the products with CE marking recognition.
โ€ข In June 2020, iVascular SLU, a medical device company, announced the global launch of its novel coronary artery drug-coated balloon. The product โ€“ Essential Pro โ€“ has several improvements over its predecessor.
โ€ข In March 2021, MedAlliance announced that it had received FDA approval for its drug-eluting coronary balloon. The product is called the Selution SLR Limus Sustained Release Drug Eluting Balloon Catheter. He received a green light for his design, which improves luminal diameter in people with atherosclerotic lesions.

๐—ž๐—ฒ๐˜† ๐—–๐—ผ๐—บ๐—ฝ๐—ฎ๐—ป๐—ถ๐—ฒ๐˜€ :
โ€ข Cardionovum GmbH
โ€ข Medical Cook INC
โ€ข Cordis Corporation
โ€ข Abbott Laboratories
โ€ข Meril Life Sciences Pvt Ltd
โ€ข Jotech GmbH
โ€ข MicroPort Scientific Corporation
โ€ข Terumo Corporation
โ€ข Boston Scientific Society

๐— ๐—ฎ๐—ฟ๐—ธ๐—ฒ๐˜ ๐—ฆ๐—ฒ๐—ด๐—บ๐—ฒ๐—ป๐˜๐˜€ ๐—ผ๐—ณ ๐——๐—ฟ๐˜‚๐—ด ๐—˜๐—น๐˜‚๐˜๐—ถ๐—ป๐—ด ๐—–๐—ฎ๐˜๐—ต๐—ฒ๐˜๐—ฒ๐—ฟ ๐—œ๐—ป๐—ฑ๐˜‚๐˜€๐˜๐—ฟ๐˜† ๐—ฆ๐˜‚๐—ฟ๐˜ƒ๐—ฒ๐˜†๐—ฟ๐—ธ๐—ฒ๐˜ ๐—ง๐—ฎ๐˜…๐—ผ๐—ป๐—ผ๐—บ๐˜† ๐—ง๐—ฎ๐˜…๐—ผ๐—ป๐—ผ๐—บ๐˜† ๐—ง๐—ฎ๐˜…๐—ผ๐—ป๐—ผ๐—บ๐˜† ๐—ง๐—ฎ๐˜…๐—ผ๐—ป๐—ผ๐—บ๐˜† ๐—ง๐—ฎ๐˜…๐—ผ๐—ป๐—ผ๐—บ๐˜† ๐—ง๐—ฎ๐˜…๐—ผ๐—ป๐—ผ๐—บ๐˜† ๐—ง๐—ฎ๐˜…๐—ผ๐—ป๐—ผ๐—บ๐˜† ๐—ง๐—ฎ๐˜…๐—ผ๐—ป๐—ผ๐—บ๐˜† ๐—ง๐—ฎ๐˜…๐—ผ๐—ป๐—ผ๐—บ๐˜† ๐—ง๐—ฎ๐˜…๐—ผ๐—ป๐—ผ๐—บ๐˜† ๐—ง๐—ฎ๐˜…๐—ผ๐—ป๐—ผ๐—บ๐˜† ๐—ง๐—ฎ๐˜…๐—ผ๐—ป๐—ผ๐—บ๐˜† ๐—ง๐—ฎ๐˜…๐—ผ๐—ป๐—ผ๐—บ๐˜†

By indication:
โ€ข Drug eluting balloon catheters for coronary artery disease
โ€ข Drug-eluting balloon catheters for peripheral vascular disease

Per end user:
โ€ข Hospitals
โ€ข Ambulatory surgery centers
โ€ข Cardiac catheterization laboratories

By raw material:
โ€ข Drug-eluting polyurethane balloon catheters
โ€ข Drug-eluting nylon balloon catheters
โ€ข Others

๐—™๐—ผ๐—ฟ ๐— ๐—ผ๐—ฟ๐—ฒ ๐—œ๐—ป๐˜€๐—ถ๐—ด๐—ต๐˜๐˜€:

https://www.prnewswire.com/news-releases/crunching-need-for-bopp-metallized-films-to-create-us-3-72-bn-opportunity-by-2032โ€“301571941.html

https://www.prnewswire.com/news-releases/magnesium-chloride-market-to-exceed-us-2-74-bn-by-2032-as-application-in-pharmaceutical-and-foodโ€“beverage -sectors-mounts-301572903.html

https://www.prnewswire.com/news-releases/booming-motorsport-industry-to-steer-lap-timers-market-past-us-345-mn-by-2032-301573991.html

Contact:
USA Sales Office:
11140 Rockville Pike
Office 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583
Email: sales@factmr.co

About Us:
Market research and consulting agency that makes the difference! Thatโ€™s why 80% of Fortune 1000 companies trust us to make their most critical decisions. Although our experienced consultants use the latest technology to extract hard-to-find information, we believe that our USP is the trust our clients place in our expertise. Covering a wide spectrum โ€“ from automotive and Industry 4.0 to healthcare and retail, our coverage is extensive, but we ensure that even the most niche categories are analyzed. Our sales offices in the USA and Dublin, Ireland. Headquarters based in Dubai, United Arab Emirates. Contact us with your goals and we will be a competent research partner.

This press release was published on openPR.